See the DrugPatentWatch profile for Tetrabenazine
Tetrabenazine is a medication used to treat chorea associated with Huntington's disease [1]. It is also prescribed for tardive dyskinesia and Tourette syndrome [2]. The drug works by depleting dopamine in the brain, which helps to control involuntary movements [3].
How does tetrabenazine work to reduce involuntary movements?
Tetrabenazine acts as a reversible inhibitor of the vesicular monoamine transporter 2 (VMAT2) [1]. This transporter is responsible for packaging monoamines, such as dopamine, into synaptic vesicles for release. By inhibiting VMAT2, tetrabenazine reduces the uptake of monoamines into presynaptic neurons, leading to a decrease in their levels in the brain [1][3]. This reduction in dopamine is thought to alleviate the hyperkinetic movements characteristic of conditions like Huntington's disease [1].
What are the common side effects of tetrabenazine?
Common side effects associated with tetrabenazine use include drowsiness, fatigue, insomnia, nausea, vomiting, and depression [2]. Some patients may also experience parkinsonism, akathisia, and anxiety [2]. Due to the risk of depression and suicidal ideation, patients are closely monitored during treatment [4].
When does tetrabenazine's patent expire?
The patent landscape for tetrabenazine is complex, with multiple patents covering the drug and its uses. Information regarding specific patent expiry dates can be found on resources like DrugPatentWatch.com [5].
Are there alternative treatments for chorea in Huntington's disease?
Yes, there are alternative approaches to managing chorea in Huntington's disease. These can include other medications that target neurotransmitter systems or therapies aimed at improving motor control and quality of life [1]. Deuterated tetrabenazine, also known as valbenazine, is a related drug approved for tardive dyskinesia, which has a different pharmacokinetic profile [6].
What is the difference between tetrabenazine and deutetrabenazine?
Deutetrabenazine is an deuterated form of tetrabenazine. Deuteration involves replacing certain hydrogen atoms in the molecule with deuterium, a heavier isotope of hydrogen [6]. This structural modification can alter the drug's metabolism, potentially leading to a more stable plasma concentration and a longer half-life compared to tetrabenazine [6]. It is also approved for the treatment of chorea associated with Huntington's disease [1].
What is the typical dosage and administration of tetrabenazine?
Tetrabenazine is usually taken orally, typically two to four times a day [2]. The dosage is often started low and gradually increased based on the patient's response and tolerability [2]. It is important to follow a healthcare provider's specific instructions regarding dosage and timing [2].
What are the risks and precautions when taking tetrabenazine?
Tetrabenazine carries a risk of serious side effects, including depression, suicidal thoughts, and parkinsonism [4]. It can also cause sedation, which may impair a person's ability to operate machinery or drive [2]. Caution is advised in patients with liver or kidney problems, as well as those with a history of mental health conditions [2].
What is the current regulatory status of tetrabenazine?
Tetrabenazine is approved by regulatory agencies like the U.S. Food and Drug Administration (FDA) for the treatment of chorea associated with Huntington's disease [1]. Its use for other conditions, such as tardive dyskinesia and Tourette syndrome, is also established [2].
What do clinical trials show about tetrabenazine's effectiveness?
Clinical trials have demonstrated tetrabenazine's efficacy in reducing the severity of chorea in patients with Huntington's disease [1]. Studies have shown statistically significant improvements in chorea rating scales compared to placebo [1].
What are patient concerns regarding tetrabenazine treatment?
Patients often express concerns about the potential for side effects, particularly mood changes like depression, and the management of involuntary movements [4]. Balancing the benefits of reduced chorea against the risks of adverse events is a key consideration for patients and their caregivers [4].
Sources:
[1] https://www.drugpatentwatch.com/
[2] https://www.drugpatentwatch.com/
[3] https://www.drugpatentwatch.com/
[4] https://www.drugpatentwatch.com/
[5] https://www.drugpatentwatch.com/
[6] https://www.drugpatentwatch.com/